DNAGinkgo+Platform TWSTTwist+Synthesis ABSIAbsci+AIDesign CRSPCRISPR Therapeutics+Edit BEAMBeam+BaseEdit NTLAIntellia+InVivo CRBUCaribou+CellTherapy RXRXRecursion+AI ILMNIllumina+Seq EDITEditas+Gene

Company Tracker

Every synthetic biology company — funding, leadership, platforms, verticals, and status.

Companies Tracked57

Active41

Total Funding on Record$17.1B+ tracked

Company	HQ	CEO	Total Funding	Products	Status
Ginkgo Bioworks	Boston, MA, USA	Jason Kelly	$2.8B+	foundry-platform, concentric-biosecurity	public
Twist Bioscience	South San Francisco, CA, USA	Emily Leproust	$900M+	synthetic-dna, gene-fragments, variant-libraries +1	public
Mammoth Biosciences	Brisbane, CA, USA	Trevor Martin	$600M+	crispr-therapeutics, detectr-diagnostics	active
ArsenalBio	South San Francisco, CA, USA	Ken Drazan	$830M+	programmable-cell-therapy	active
EvolutionaryScale	New York, NY, USA	Alexander Rives	$682M+	esm3-protein-model, esm4-protein-model	active
Cradle	Amsterdam, Netherlands	Stef van Grieken	$103M+	ai-protein-engineering	active
Absci Corporation	Vancouver, WA, USA	Sean McClain	$500M+	integrated-drug-creation, solupro	public
Solugen	Houston, TX, USA	Gaurab Chakrabarti	$600M+	bioforge, bio-hydrogen-peroxide, glucaric-acid	active
Perfect Day	Berkeley, CA, USA	Ryan Pandya	$750M+	proferm-whey, brave-robot	active
LanzaTech	Skokie, IL, USA	Jennifer Holmgren	$600M+	gas-fermentation, sustainable-aviation-fuel	public
Pivot Bio	Berkeley, CA, USA	Karsten Temme	$600M+	proven-40, proven-corn, proven-wheat	active
Benchling	San Francisco, CA, USA	Sajith Wickramasekara	$400M+	eln, lims, registry +1	active
Synthego	Redwood City, CA, USA	Paul Dabrowski	$300M+	guide-rnas, crispr-kits, engineered-cells	active
Generate Biomedicines	Somerville, MA, USA	Mike Nally	$700M+	generative-protein-therapeutics	active
bit.bio	Cambridge, UK	Mark Kotter	$200M+	opti-ox, ioGlutamatergic-neurons, ioCardiomyocytes	active
Arzeda	Seattle, WA, USA	Alexandre Zanghellini	$70M+	computational-enzyme-design	active
Strand Therapeutics	Cambridge, MA, USA	Jake Becraft	$200M+	programmable-mrna	active
Chroma Medicine	Cambridge, MA, USA	Catherine Stehman-Breen	$260M+	epigenome-editing	active
Caribou Biosciences	Berkeley, CA, USA	Rachel Haurwitz	$400M+	chrdna-crispr, allogeneic-car-t	public
Tune Therapeutics	Durham, NC, USA	Fyodor Urnov (co-founder)	$275M+	tempo-epigenome-platform	active
Bolt Threads	Emeryville, CA, USA	Dan Widmaier	$500M+	mylo-mycelium-leather, microsilk	active
MycoWorks	Emeryville, CA, USA	Matt Scullin	$200M+	reishi-fine-mycelium	active
Synonym	New York, NY, USA	Edward Shenderovich	$50M+	capacitor-database, biomanufacturing-design	active
Pow.bio	Berkeley, CA, USA	Moji Karimi	$30M+	continuous-fermentation-cdmo	active
National Resilience	San Diego, CA, USA	Rahul Singhvi	$2B+	biomanufacturing-cdmo, gene-therapy-manufacturing, mrna-manufacturing	active
Inari Agriculture	Cambridge, MA, USA	Ponsi Trivisvavet	$400M+	seedesign-crops	active
Benson Hill	St. Louis, MO, USA	Deanie Elsner	$500M+	high-protein-soybeans, ultra-high-oleic	defunct
Meatable	Delft, Netherlands	Krijn de Nood	$100M+	cultivated-pork, cultivated-beef	active
Aleph Farms	Rehovot, Israel	Didier Toubia	$200M+	cultivated-beef-steak	active
Nobell Foods	San Francisco, CA, USA	Magi Richani	$120M+	plant-produced-casein	active
Provivi	Santa Monica, CA, USA	Pedro Coelho	$100M+	pherogen-crop-protection	active
Living Carbon	San Francisco, CA, USA	Maddie Hall	$50M+	photosynthesis-enhanced-trees	active
Synthace	London, UK	Markus Gershater	$60M+	antha-platform	active
Strateos	San Diego, CA, USA	Mark Fischer	$60M+	smartlab-cloud-laboratory	active
Spiber	Tsuruoka, Yamagata, Japan	Kazuhide Sekiyama	$700M+	brewed-protein	active
Ecovative Design	Green Island, NY, USA	Eben Bayer	$120M+	airmycelium, mybacon, myforest-foods	active
Cemvita Factory	Houston, TX, USA	Moji Adesina	$40M+	bioethylene, gold-hydrogen, biosurfactants	active
Mango Materials	Redwood City, CA, USA	Molly Morse	$25M+	pha-bioplastics	active
Volta Labs	Cambridge, MA, USA	Udayan Umapathi	$50M+	callisto-digital-fluidics	active
Senti Biosciences	South San Francisco, CA, USA	Tim Lu	$300M+	gene-circuit-cell-therapy	public
Zymergen (acquired by Ginkgo)	Emeryville, CA, USA (formerly)	N/A (acquired)	$1B+	microbial-engineering	acquired
ARCH Venture Partners	Chicago, IL, USA	Robert Nelsen (Managing Director)	N/A		active
DCVC Bio	San Francisco, CA, USA	Kiersten Stead (Managing Partner)	N/A		active
Lux Capital	New York, NY, USA	Josh Wolfe (Managing Partner)	N/A		active
Khosla Ventures	Menlo Park, CA, USA	Vinod Khosla (Founder)	N/A		active
a16z Bio (Andreessen Horowitz)	Menlo Park, CA, USA	Jorge Conde (General Partner)	N/A		active
Flagship Pioneering	Cambridge, MA, USA	Noubar Afeyan (Founder & CEO)	N/A		active
Recursion Pharmaceuticals	Salt Lake City, UT, USA	Chris Gibson	$1B+	recursion-os, phenomics-platform	public
Illumina	San Diego, CA, USA	Jacob Thaysen	N/A (public since 2000)	novaseq-x, miseq, nextseq	public
Beam Therapeutics	Cambridge, MA, USA	John Evans	$700M+	base-editing-therapeutics	public
Intellia Therapeutics	Cambridge, MA, USA	John Leonard	$1B+	in-vivo-crispr-editing	public
CRISPR Therapeutics	Zug, Switzerland / Cambridge, MA, USA	Samarth Kulkarni	$1.5B+	casgevy, crispr-cell-therapy	public
Editas Medicine	Cambridge, MA, USA	Gilmore O'Neill	$700M+	in-vivo-gene-editing, reni-cel	public
Verve Therapeutics	Cambridge, MA, USA	Andrew Bellinger	$600M+	base-editing-cardiovascular	public
Sana Biotechnology	Seattle, WA, USA	Steve Harr	$1B+	hypoimmune-cell-therapy, in-vivo-cell-engineering, fusogen-delivery	public
Scribe Therapeutics	California, USA		$120M	epigenetic-silencing, stx-1150	active
Serapha Bio			$230M	serp-01, hepdone-platform	active